Ocriplasmin

N/A

Report date: 2022/01/14 13:23:58
First In Class

Base Information

Drug NameOcriplasmin
Drug Alias Nameocriplasmine奥克纤溶酶Recombinant microplasmin奥克利纤溶酶ocriplasminum +[12] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionCollagen stimulantsGalectin-3 inhibitorsGalectin-1 inhibitors +[4] 
TargetsCollagenGalectin-3Galectin-1 +[4] 
Therapy Area/IndicationsDiabetic macular oedemaVitreomacular AdhesionDisease Progression +[13] 
Global Approved IndicationsVitreomacular AdhesionRetinal Diseases
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2012/10/17
Country/TerritoryCzechiaBelgiumUnited States +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesThrombogenics
China Registration ClassN/A

Develop Information

Active CompaniesThrombogenics IncInceptua AB
Inactive CompaniesNational Institutes Of Health Clinical Center (Cc)AlconUniversitaire Ziekenhuizen Leuven +[5] 
Active IndicationsVitreomacular AdhesionRetinal Diseases
Inactive IndicationsDiabetic macular oedemaDisease ProgressionVenous Thrombosis +[11] 

Other Information

ATC CodeS01XA22
Related LinksWikipediaDrugBankKEGG